The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges

Figure 3

5-year disease-free survival rate analysis of TNBC patients treated with anthracycline-based adjuvant chemotherapy. At 5 years of follow up, the TNBC patients were grouped according to their PITX2 DNA methylation value with a cut-off of 6.35 percent methylation ratio (PMR). Low PITX2 DNA methylation status () shows a poor disease-free survival rate at 5 years (35.6%); high PITX2 DNA methylation status () is associated at 5-year observation time with favorable disease-free survival (83.5%). ( values: log-rank test, ; Wilcoxon test, ) [66].